和黄医药涨逾5% SACHI III期研究结果于《柳叶刀》发表

智通财经01-16

周五，和黄医药(HCM.US)涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼(savolitinib)和奥希替尼(osimertinib)的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。据悉，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604446209?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-16 23:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2604446209","market":"us","top_or_hot":-1,"title":"和黄医药涨逾5% SACHI III期研究结果于《柳叶刀》发表","media":"智通财经","content":"<div>\n<p>周五，和黄医药(HCM.US)涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼(savolitinib)和奥希替尼(osimertinib)的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。据悉，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药涨逾5% SACHI III期研究结果于《柳叶刀》发表</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药涨逾5% SACHI III期研究结果于《柳叶刀》发表\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 23:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周五，和黄医药(HCM.US)涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼(savolitinib)和奥希替尼(osimertinib)的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。据悉，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b","article_id":"2604446209","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116232631a72389bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604446209","pubTimestamp":1768576666,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"周五，和黄医药涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼和奥希替尼的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体酪氨酸激酶抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","HCM":"和黄医药","BK4134":"信息科技咨询与其它服务","BK4007":"制药","BK4531":"中概回港概念","III":"信息服务","BK4588":"碎股"},"translate_title":"Chi-Med rose more than 5%, results of SACHI phase III study published in The Lancet","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1.5,"III":1.5},"content_text":"周五，和黄医药(HCM.US)涨逾5%，报16.12美元。消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼(savolitinib)和奥希替尼(osimertinib)的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。据悉，赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。奥希替尼是一种不可逆的第三代EGFR TKI。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604446209","isCrawlerRequest":true}